Finn
DFTX Biotechnology · Clinical stage · Brain health · Psychedelics · Thesis updated November 15, 2026

Positive anxiety data clears path for an NDA filing

01 Running thesis

A de-risked path to regulatory review

Definium has de-risked its lead asset by delivering highly positive data across its late-stage pipeline. The lead drug candidate, DT120, met its primary and all key secondary endpoints in both Phase 3 pivotal trials for generalized anxiety disorder. These trials, Voyage and Panorama, demonstrated clear placebo-adjusted improvements. This success follows a similar victory in the Phase 3 Emerge trial for major depressive disorder.

The bull case is driven by clinical momentum. DT120 now holds FDA Breakthrough Therapy designations for both generalized anxiety disorder and major depressive disorder. Management is targeting a New Drug Application filing in the first half of 2027. Outside of DT120, a Phase 2a trial for a second candidate in autism spectrum disorder was stopped early because it showed a strong positive signal.

Execution remains strong, and financing risk is largely off the table. Definium ended the third quarter of 2026 with $1.05 billion in cash. This balance provides a clear runway into 2030, ensuring the company can fund operations through the regulatory review period and initial commercial planning.

The bear case remains tied to the novel nature of these treatments and commercial rollout. These are psychedelic-derived and empathogen-derived drugs. The FDA must accept the trial design, including efforts to handle functional unblinding, where patients might guess they received the active drug because they feel its effects. Schedule I drug rules could also slow commercial launch because the Drug Enforcement Administration will need to make scheduling decisions after any FDA approval.

Nov 2026▲Phase 3 Voyage and Panorama trials met all endpoints. FDA granted Breakthrough Therapy for MDD, and management targeted an NDA filing in the first half of 2027.
Aug 2026▲The Phase 3 Emerge trial for MDD met all primary and secondary endpoints, and a successful equity offering extended the cash runway into 2030.
May 2026▲Q1 2026 filings added the Haven Phase 3 PTSD plan and showed Panorama completed SSRE, passed its 200 participant target, and closed screening.
Feb 2026▲The company rebranded to Definium Therapeutics and began trading as DFTX. Year-end cash balances supported runway guidance into 2028.
Feb 2026▲Voyage completed its SSRE with no sample size increase needed. Management also set the readout order, with Emerge expected first in late Q2 2026.
Nov 2025▲Management moved the Emerge MDD readout earlier after faster enrollment. Phase 2b data showed strong placebo-adjusted reduction at week 12.
02 Business model

Patents first, sales later

Definium does not yet make money from an approved drug. Today, the company spends cash to run trials, manufacture study drugs, manage regulators, and protect its drug designs. If a product is approved, revenue would likely come from selling the medicine, partnering it, or both.

Its defense depends on intellectual property. The lead candidate, DT120 ODT, is protected by patents on formulation and manufacturing methods that extend through 2041. That matters because lysergide itself is old, so Definium needs its optimized tablet form, trial data, manufacturing know-how, and patents to protect long-term value.

The financial model requires massive capital to fund late-stage trials. Fortunately, Definium has secured its balance sheet. With over $1 billion in cash reported in late 2026, management stated that funds will be sufficient to support operations into 2030. This removes the near-term need to raise expensive equity while waiting for regulatory decisions.

03 Product portfolio

DT120 carries the story

Growth engine

DT120 ODT for GAD, Voyage and Panorama

Voyage and Panorama are Phase 3 GAD trials that successfully met all primary and secondary endpoints in late 2026.

Growth engine

DT120 ODT for MDD, Emerge

Emerge is a Phase 3 MDD trial that successfully met its primary and all key secondary efficacy endpoints in June 2026.

Option

DT120 ODT for MDD, Ascend

Ascend is the second Phase 3 MDD trial and began dosing in mid-2026.

Option

DT120 ODT for PTSD, Haven

Haven is a planned Phase 3 PTSD trial expected to initiate in 2027.

Option

DT402 for ASD

DT402 is a proprietary candidate for autism spectrum disorder. Its Phase 2a trial was stopped early in 2026 due to strong efficacy signals.

04 Business segments

Spending, not sales

Research and development expense70%growing fast
General and administrative expense30%growing fast

Definium is clinical stage, so it does not report a product revenue mix. Operating expenses are primarily allocated across research and development and general administrative costs based on late 2026 disclosures.

05 Risk factors

What can break

Regulatory review rejections

High impact · Medium odds

Despite positive Phase 3 data, the FDA can still reject a New Drug Application. The agency might question the safety database, manufacturing controls, or the specific statistical meaning of the results.

We watchFDA communications, advisory committee dates, and the final NDA acceptance decision in 2027.

Functional unblinding

High impact · Medium odds

Psychedelic effects can be obvious to patients. If patients know they received the active drug, the FDA may question the proven benefit. Definium uses trial design tools to reduce this risk.

We watchFDA comments on trial design, advisory committee discussions, and final label negotiations.

Schedule I delays

High impact · Medium odds

DT120 and DT402 are tied to compounds treated as Schedule I controlled substances. Even with FDA approval, DEA scheduling decisions may be needed before broad commercial launch.

We watchDEA scheduling actions after any FDA approval or public FDA review documents.

Commercial access after approval

Medium impact · Medium odds

Even an effective drug may be hard to launch if dosing requires special sites, trained staff, or long patient visits. Payers may also demand proof that the treatment lowers total care costs.

We watchPre-launch plans, payer feedback, site network buildout, and label language.
06 Quick answers

In one breath

What does Definium Therapeutics do?

Definium develops drug candidates for brain health disorders. Its lead drug, DT120 ODT, has completed Phase 3 trials for generalized anxiety disorder.

When is the Definium NDA filing expected?

The company targets filing a New Drug Application with the FDA in the first half of 2027.

Does DFTX have revenue today?

The company is clinical stage and does not have an approved product. Its financial story revolves around cash runway, trial spending, and clinical data.

Why does Schedule I status matter for DFTX?

Schedule I drugs face extra legal controls. If DT120 or DT402 wins FDA approval, DEA scheduling decisions may still be needed before the drug can be sold broadly.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. DFTX Q3 2026 Form 10-Q
  2. DFTX Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Definium Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today